Overview

Price chart · mood · technical indicators

SLS

Sellas Life Sciences Group Incstock Healthcare

Biotechnology

$7.83386.34%Current Market Mood:Bullish

Market Mood

Price Range (1Y)

$1.39$9.51

Current: $7.83

Market Comparison

vs Healthcare Sector & Biotechnology Industry

SLS

+386.34%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-0.230.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$1.54BSmall cap

Wall Street coverage

$10.00median target· current $1.50 (+566.7%)2 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 14.19
P/S (TTM): 26.90
EV/EBITDA: -1.71

Profitability & growth

ROE (TTM): -43.6%
Operating margin: 0.0%
Revenue growth YoY: -82.5%
Dividend yield: —
Beta: 2.53

Last earnings

May 12, 2026 · Estimate $-0.07 · Reported $-0.05

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Sellas Life Sciences Group Inc

Company profile

SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 7 TIMES SQUARE, NEW YORK, NY
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$1.54B

Shares outstanding$196.6M

52W high$9.51

52W low$1.39

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

SLS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute

SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout

SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute

SLS Stock Jumps As Earnings Beat Fuels Biotech Momentum

Sellas Life Sciences reports $28.7 million from warrant exercises, updates share count

Why SELLAS Life Sciences Group (SLS) Is Up 19.7% After Cramer Endorsement And REGAL Trial Focus

SELLAS Life Sciences Group, Inc. Files Form 8-K with SEC – Company Details, Address, and NASDAQ Listing Information

SELLAS Life Sciences (NASDAQ: SLS) reports cash and warrant proceeds

Jim Cramer on SELLAS: “It’s a Great Spec”

Sellas Life Sciences stock hits 52-week high at 9.11 USD

Sellas Life Sciences stock hits 52-week high at 9.11 USD

SELLAS Life Sciences Group Inc (SLS) Earnings, Actual EPS, EPS Estimates & Results

SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms

SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS

Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal (NASDAQ:SLS)

SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst

SLS Stock Rallies After Hours As CEO Teases Leukemia Study Data Any Day Now

SLS Stock Pulls Back As Cash Pile Extends Biotech Runway

SLS: Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials

SLS Stock Jumps As Cash Pile Grows And Trial Catalysts Near

About Sellas Life Sciences Group Inc

Classification

Company profile

SLS

Market Comparison

SLS Market Analysis

Overview

SLS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute

SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout

SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute

SLS Stock Jumps As Earnings Beat Fuels Biotech Momentum

Sellas Life Sciences reports $28.7 million from warrant exercises, updates share count

Why SELLAS Life Sciences Group (SLS) Is Up 19.7% After Cramer Endorsement And REGAL Trial Focus

SELLAS Life Sciences Group, Inc. Files Form 8-K with SEC – Company Details, Address, and NASDAQ Listing Information

SELLAS Life Sciences (NASDAQ: SLS) reports cash and warrant proceeds

Jim Cramer on SELLAS: “It’s a Great Spec”

Sellas Life Sciences stock hits 52-week high at 9.11 USD

Sellas Life Sciences stock hits 52-week high at 9.11 USD

SELLAS Life Sciences Group Inc (SLS) Earnings, Actual EPS, EPS Estimates & Results

SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms

SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS

Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal (NASDAQ:SLS)

SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst

SLS Stock Rallies After Hours As CEO Teases Leukemia Study Data Any Day Now

SLS Stock Pulls Back As Cash Pile Extends Biotech Runway

SLS: Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials

SLS Stock Jumps As Cash Pile Grows And Trial Catalysts Near

About Sellas Life Sciences Group Inc

Classification

Company profile

SLS

Market Comparison